Compare STRA & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STRA | ZYME |
|---|---|---|
| Founded | 2017 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.9B |
| IPO Year | 1996 | 2022 |
| Metric | STRA | ZYME |
|---|---|---|
| Price | $79.40 | $24.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $87.00 | $38.90 |
| AVG Volume (30 Days) | 285.9K | ★ 556.7K |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.04% | N/A |
| EPS Growth | 15.85 | ★ 33.33 |
| EPS | ★ 1.48 | N/A |
| Revenue | ★ $997,137,000.00 | $105,965,000.00 |
| Revenue This Year | $4.71 | $183.10 |
| Revenue Next Year | $4.67 | N/A |
| P/E Ratio | $54.13 | ★ N/A |
| Revenue Growth | ★ 57.23 | 38.87 |
| 52 Week Low | $69.70 | $11.02 |
| 52 Week High | $92.98 | $29.75 |
| Indicator | STRA | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 51.10 | 45.50 |
| Support Level | $78.41 | $24.79 |
| Resistance Level | $84.97 | $27.54 |
| Average True Range (ATR) | 2.13 | 1.21 |
| MACD | 0.32 | -0.22 |
| Stochastic Oscillator | 59.72 | 33.92 |
Strategic Education Inc. is an education services company that provides access to high-quality education through campus-based and online post-secondary education offerings, as well as through programs to develop job-ready skills for high-demand markets. The company operates through wholly-owned subsidiaries Strayer University and Capella University, both accredited post-secondary institutions of higher education located in the United States, as well as Torrens University, an accredited post-secondary institution of higher education located in Australia. It provide employees with access to affordable and industry relevant training, certificate, and degree programs. The reportable segments of the company are U.S. Higher Education, Australia/New Zealand and Education Technology Services.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.